Agenus (AGEN) Competitors $3.34 +0.48 (+16.78%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AGEN vs. ALGS, DTIL, ADAP, LXRX, VSTM, ACHV, RGLS, FBIO, SABS, and CRISShould you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Aligos Therapeutics (ALGS), Precision BioSciences (DTIL), Adaptimmune Therapeutics (ADAP), Lexicon Pharmaceuticals (LXRX), Verastem (VSTM), Achieve Life Sciences (ACHV), Regulus Therapeutics (RGLS), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), and Curis (CRIS). These companies are all part of the "medical" sector. Agenus vs. Aligos Therapeutics Precision BioSciences Adaptimmune Therapeutics Lexicon Pharmaceuticals Verastem Achieve Life Sciences Regulus Therapeutics Fortress Biotech SAB Biotherapeutics Curis Agenus (NASDAQ:AGEN) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, community ranking, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability. Which has preferable earnings & valuation, AGEN or ALGS? Aligos Therapeutics has lower revenue, but higher earnings than Agenus. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgenus$156.31M0.50-$245.76M-$11.24-0.30Aligos Therapeutics$15.53M4.63-$87.68M-$13.32-1.50 Do institutionals and insiders hold more shares of AGEN or ALGS? 61.5% of Agenus shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 4.6% of Agenus shares are owned by company insiders. Comparatively, 8.8% of Aligos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer AGEN or ALGS? Agenus received 440 more outperform votes than Aligos Therapeutics when rated by MarketBeat users. Likewise, 69.49% of users gave Agenus an outperform vote while only 65.85% of users gave Aligos Therapeutics an outperform vote. CompanyUnderperformOutperformAgenusOutperform Votes46769.49% Underperform Votes20530.51% Aligos TherapeuticsOutperform Votes2765.85% Underperform Votes1434.15% Is AGEN or ALGS more profitable? Agenus has a net margin of -145.89% compared to Aligos Therapeutics' net margin of -1,283.19%. Agenus' return on equity of 0.00% beat Aligos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Agenus-145.89% N/A -85.68% Aligos Therapeutics -1,283.19%-114.34%-64.58% Do analysts prefer AGEN or ALGS? Agenus presently has a consensus target price of $10.00, suggesting a potential upside of 199.40%. Aligos Therapeutics has a consensus target price of $75.00, suggesting a potential upside of 274.25%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aligos Therapeutics is more favorable than Agenus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agenus 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, AGEN or ALGS? Agenus has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Does the media favor AGEN or ALGS? In the previous week, Agenus had 11 more articles in the media than Aligos Therapeutics. MarketBeat recorded 12 mentions for Agenus and 1 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.00 beat Agenus' score of -0.23 indicating that Aligos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAgenus beats Aligos Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Darwin2024 Election Year Stocks: Uncover Hidden Gems!In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.Secure your copy now by clicking this link. Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGEN vs. The Competition Export to ExcelMetricAgenusBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$78.36M$3.04B$5.38B$8.84BDividend YieldN/A1.91%5.13%4.09%P/E Ratio-0.3045.50105.0417.81Price / Sales0.50392.401,235.79158.52Price / CashN/A169.3840.3536.29Price / Book-0.294.597.086.50Net Income-$245.76M-$41.63M$119.58M$226.22M7 Day Performance22.79%2.61%2.25%4.03%1 Month Performance-25.61%-2.47%-2.34%4.92%1 Year Performance-75.41%28.24%33.95%29.30% Agenus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGENAgenus3.8917 of 5 stars$3.34+16.8%$10.00+199.4%-75.4%$78.36M$156.31M-0.30389Analyst RevisionGap DownALGSAligos Therapeutics3.8379 of 5 stars$19.68+8.1%$75.00+281.2%+17.9%$70.63M$15.53M-1.4990High Trading VolumeDTILPrecision BioSciences4.043 of 5 stars$6.50-9.5%$39.50+507.7%-42.9%$49.86M$48.73M109.02200High Trading VolumeADAPAdaptimmune Therapeutics2.122 of 5 stars$0.63-4.5%$3.16+399.5%+47.3%$162.00M$60.28M-2.88449LXRXLexicon Pharmaceuticals1.9776 of 5 stars$0.78-3.7%$6.00+669.1%-21.5%$192.09M$1.20M0.00285Analyst ForecastGap DownVSTMVerastem2.7519 of 5 stars$3.93+3.7%$12.50+218.1%-37.8%$174.92M$2.60M-1.2350Analyst DowngradeAnalyst RevisionNews CoverageACHVAchieve Life Sciences1.3346 of 5 stars$4.33+0.5%$14.80+242.2%-16.9%$148.74MN/A-3.8320RGLSRegulus Therapeutics2.4611 of 5 stars$1.40flat$10.80+671.4%+13.1%$91.70MN/A-1.3130News CoverageFBIOFortress Biotech3.0759 of 5 stars$1.58flat$13.67+767.7%-26.8%$43.47M$84.51M-0.52186Analyst RevisionSABSSAB Biotherapeutics3.3228 of 5 stars$3.07+0.3%$12.40+303.9%+235.5%$28.34M$2.24M0.00140Gap UpCRISCuris2.0786 of 5 stars$4.10+10.8%$23.00+461.0%-51.9%$24.52M$10.02M-0.5149High Trading Volume Related Companies and Tools Related Companies Aligos Therapeutics Alternatives Precision BioSciences Alternatives Adaptimmune Therapeutics Alternatives Lexicon Pharmaceuticals Alternatives Verastem Alternatives Achieve Life Sciences Alternatives Regulus Therapeutics Alternatives Fortress Biotech Alternatives SAB Biotherapeutics Alternatives Curis Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AGEN) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGEN Stock Alerts